S&P 500   3,934.11 (-0.18%)
DOW   33,617.94 (+0.06%)
QQQ   280.41 (-0.45%)
AAPL   141.26 (-1.15%)
MSFT   244.50 (-0.25%)
META   113.66 (-0.40%)
GOOGL   95.27 (-1.76%)
AMZN   88.01 (-0.27%)
TSLA   173.57 (-3.48%)
NVDA   159.75 (-0.08%)
NIO   12.62 (-4.68%)
BABA   88.81 (-2.89%)
AMD   70.71 (+0.63%)
T   19.39 (+1.15%)
MU   53.58 (-0.19%)
CGC   3.31 (-8.31%)
F   13.30 (+0.15%)
GE   85.43 (+0.18%)
DIS   92.43 (+0.15%)
AMC   6.45 (-4.44%)
PYPL   73.96 (+2.40%)
PFE   50.46 (+1.51%)
NFLX   306.77 (+0.40%)
S&P 500   3,934.11 (-0.18%)
DOW   33,617.94 (+0.06%)
QQQ   280.41 (-0.45%)
AAPL   141.26 (-1.15%)
MSFT   244.50 (-0.25%)
META   113.66 (-0.40%)
GOOGL   95.27 (-1.76%)
AMZN   88.01 (-0.27%)
TSLA   173.57 (-3.48%)
NVDA   159.75 (-0.08%)
NIO   12.62 (-4.68%)
BABA   88.81 (-2.89%)
AMD   70.71 (+0.63%)
T   19.39 (+1.15%)
MU   53.58 (-0.19%)
CGC   3.31 (-8.31%)
F   13.30 (+0.15%)
GE   85.43 (+0.18%)
DIS   92.43 (+0.15%)
AMC   6.45 (-4.44%)
PYPL   73.96 (+2.40%)
PFE   50.46 (+1.51%)
NFLX   306.77 (+0.40%)
S&P 500   3,934.11 (-0.18%)
DOW   33,617.94 (+0.06%)
QQQ   280.41 (-0.45%)
AAPL   141.26 (-1.15%)
MSFT   244.50 (-0.25%)
META   113.66 (-0.40%)
GOOGL   95.27 (-1.76%)
AMZN   88.01 (-0.27%)
TSLA   173.57 (-3.48%)
NVDA   159.75 (-0.08%)
NIO   12.62 (-4.68%)
BABA   88.81 (-2.89%)
AMD   70.71 (+0.63%)
T   19.39 (+1.15%)
MU   53.58 (-0.19%)
CGC   3.31 (-8.31%)
F   13.30 (+0.15%)
GE   85.43 (+0.18%)
DIS   92.43 (+0.15%)
AMC   6.45 (-4.44%)
PYPL   73.96 (+2.40%)
PFE   50.46 (+1.51%)
NFLX   306.77 (+0.40%)
S&P 500   3,934.11 (-0.18%)
DOW   33,617.94 (+0.06%)
QQQ   280.41 (-0.45%)
AAPL   141.26 (-1.15%)
MSFT   244.50 (-0.25%)
META   113.66 (-0.40%)
GOOGL   95.27 (-1.76%)
AMZN   88.01 (-0.27%)
TSLA   173.57 (-3.48%)
NVDA   159.75 (-0.08%)
NIO   12.62 (-4.68%)
BABA   88.81 (-2.89%)
AMD   70.71 (+0.63%)
T   19.39 (+1.15%)
MU   53.58 (-0.19%)
CGC   3.31 (-8.31%)
F   13.30 (+0.15%)
GE   85.43 (+0.18%)
DIS   92.43 (+0.15%)
AMC   6.45 (-4.44%)
PYPL   73.96 (+2.40%)
PFE   50.46 (+1.51%)
NFLX   306.77 (+0.40%)
NASDAQ:CYTK

Cytokinetics - CYTK Stock Forecast, Price & News

$37.39
+0.39 (+1.05%)
(As of 12/7/2022 12:17 PM ET)
Add
Compare
Today's Range
$36.67
$37.53
50-Day Range
$36.51
$51.11
52-Week Range
$29.26
$55.80
Volume
15,553 shs
Average Volume
868,252 shs
Market Capitalization
$3.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$63.83

Cytokinetics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
72.1% Upside
$63.83 Price Target
Short Interest
Healthy
11.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.00mentions of Cytokinetics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$6.37 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.09) to ($4.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

551st out of 1,023 stocks

Pharmaceutical Preparations Industry

257th out of 501 stocks

CYTK stock logo

About Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Stock News Headlines

Is Cytokinetics (CYTK) a Good Long-Term Investment?
Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

CYTK Company Calendar

Last Earnings
11/03/2022
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTK
Employees
253
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$63.83
High Stock Price Forecast
$82.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+70.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-215,310,000.00
Net Margins
-190.34%
Pretax Margin
-190.34%

Debt

Sales & Book Value

Annual Sales
$70.43 million
Book Value
$2.91 per share

Miscellaneous

Free Float
89,899,000
Market Cap
$3.54 billion
Optionable
Optionable
Beta
1.00

Social Links


Key Executives

  • Mr. Robert I. BlumMr. Robert I. Blum (Age 58)
    CEO, Pres & Director
    Comp: $1.08M
  • Mr. Ching W. JawMr. Ching W. Jaw (Age 59)
    Sr. VP & CFO
    Comp: $645.6k
  • Dr. Fady Ibraham Malik FACC (Age 58)
    M.D., Ph.D., Exec. VP of R&D
    Comp: $733.08k
  • Mr. Andrew M. Callos (Age 66)
    Exec. VP & Chief Commercial Officer
    Comp: $411.85k
  • Dr. James A. Spudich Ph.D. (Age 80)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Jeff Lotz
    VP of Sales & Operations
  • Mr. Robert C. Wong (Age 54)
    VP & Chief Accounting Officer
  • Ms. Joanna Siegall
    Associate Director of Corp. Communications & Investor Relations
  • Ms. Kari K. Loeser J.D.
    VP & Chief Compliance Officer
  • Mr. Scott R. Jordan
    Sr. VP of Global Marketing & Commercial Strategy













CYTK Stock - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price forecast for 2023?

9 brokerages have issued 1-year price targets for Cytokinetics' stock. Their CYTK share price forecasts range from $15.00 to $82.00. On average, they expect the company's share price to reach $63.83 in the next year. This suggests a possible upside of 72.5% from the stock's current price.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2022?

Cytokinetics' stock was trading at $45.58 on January 1st, 2022. Since then, CYTK shares have decreased by 18.8% and is now trading at $37.00.
View the best growth stocks for 2022 here
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our CYTK earnings forecast
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) announced its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.09. The biopharmaceutical company earned $2.52 million during the quarter, compared to analyst estimates of $2.26 million. Cytokinetics had a negative net margin of 190.34% and a negative trailing twelve-month return on equity of 225.84%.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.40%), Vanguard Group Inc. (10.56%), State Street Corp (4.50%), Lord Abbett & CO. LLC (3.97%), RTW Investments LP (2.72%) and Pictet Asset Management SA (2.28%). Insiders that own company stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends
.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $37.00.

How much money does Cytokinetics make?

Cytokinetics (NASDAQ:CYTK) has a market capitalization of $3.50 billion and generates $70.43 million in revenue each year. The biopharmaceutical company earns $-215,310,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis.

How many employees does Cytokinetics have?

The company employs 253 workers across the globe.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cytokinetics.com. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at investor@cytokinetics.com, or via fax at 650-624-3010.

This page (NASDAQ:CYTK) was last updated on 12/7/2022 by MarketBeat.com Staff